ReNeuron’s ReN001 clinical trial features in Stroke supplement in the Independent to mark Stroke Awareness Day. For full details please click here
Stroke Awareness Day 10th May 2011. 10/05/11
ReNeuron comments on EU legal opinion on patenting of human embryonic stem cells
Guildford, UK, 28 April 2011: ReNeuron Group plc (LSE: RENE.L) notes today’s press coverage regarding an ongoing European legal case concerning the patentability of human embryonic stem cells.
ReNeuron stem cell line used to demonstrate how anti-depressants make new brain cells.
Guildford, UK, 15 April 2011: ReNeuron Group plc (LSE: RENE.L) today announces that one of its human neural stem cell lines has been used by academic researchers to show for the first time in a clinically relevant model how anti-depressant drugs make new brain cells.
ReNeuron signs manufacturing agreement with NHS Blood and Transplant for next generation stem cell product
Guildford, UK, 8 April 2011: ReNeuron Group plc (LSE: RENE.L) today announces that it is expanding its contract manufacturing arrangements in the UK by signing an agreement with NHS Blood and Transplant (NHSBT) to develop and manufacture its CTXcryoTM stem cell product to clinical and commercial grade standards.
ReNeuron to benefit from Budget and Growth Review provisions supporting UK life sciences sector
Guildford, UK, 24 March 2011: ReNeuron Group plc (LSE: RENE.L) today welcomes the significant measures announced by the Chancellor of the Exchequer in yesterday’s Budget and Growth Review in support of the UK life sciences sector.
ReNeuron flags participation at forthcoming London public stem cell forum and other key UK conferences
Guildford, UK, 4 March 2011: ReNeuron Group plc (LSE: RENE.L) today announces that it will be participating at a number of key UK stem cell and life science conferences over the course of March.
ReNeuron gives update on stroke clinical trial
Guildford, UK, 3 March 2011: ReNeuron Group plc (LSE: RENE.L) today provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The PISCES study (Pilot Investigation of Stem Cells in Stroke) is the world’s first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world.
ReNeuron stroke clinical trial leader to speak at UK public stem cell forum
Guildford, UK, 31 January 2011: ReNeuron Group plc (LSE: RENE.L) today announces that the Principal Investigator for the Company’s Phase I clinical trial in stroke will be speaking at a public stem cell forum to be held in Scotland this week.
ReNeuron settles legal dispute with US stem cell business
Guildford, UK, 28 January 2011: ReNeuron Group plc (LSE: RENE.L) today announces that it has reached a settlement with Neuralstem, Inc. (NYSE Amex: CUR) regarding the existing litigation in the US between the parties.
Result of General Meeting and Third Admission. 29/12/10
Guildford, UK, 29 December 2010: ReNeuron Group plc (LSE: RENE.L) announced on 13 December 2010 that it had raised £10 million, before expenses (the “Fundraising”), by means of:
· a placing (the “Placing”), with new and existing investors, of 181,318,182 new Ordinary Shares of 1 pence each (the “Ordinary Shares”) (the “Placing Shares”) at a price of 5.5 pence per new Ordinary Share; and
· a subscription (the “Subscription”), by the Directors, for 500,000 new Ordinary Shares of 1 pence each (the “Subscription Shares”) also at a price of 5.5 pence per new Ordinary Share.